Trials / Unknown
UnknownNCT03969576
Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)
Efficacy and Safety of Drug-eluting Bead TACE VS Conventional TACE for Unresectable Hepatocellular Carcinoma: a Multicenter, Prospective Cohort Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 344 (estimated)
- Sponsor
- Air Force Military Medical University, China · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
this multi-center prospective cohort study is to evaluate the efficacy and the safety of drug-eluting bead TACE compared with conventional TACE in terms of objective response in unresectable HCC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | DEB-TACE | Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated "on demand" according to the radiological response. |
| PROCEDURE | cTACE | Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated "on demand" according to the radiological response. |
Timeline
- Start date
- 2020-09-15
- Primary completion
- 2022-06-15
- Completion
- 2022-06-15
- First posted
- 2019-05-31
- Last updated
- 2020-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03969576. Inclusion in this directory is not an endorsement.